Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (221-230 of 238) with videos related to

Pageof 24
Sort By:
Journal of Clinical Pharmacology|September 17, 2009
Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 studyEkkehard Gruenig, Evangelos Michelakis, Jean-Luc Vachiéry, et al.
Clinical Drug Investigation|May 31, 2007
Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorderLuís Ferreira, Maria-Luísa Figueira, Alberto Bessa-Peixoto, et al.
The European Respiratory Journal|June 2, 2012
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertensionLaurent Savale, Romain Magnier, Jérôme Le Pavec, et al.
Clinical Pharmacology and Therapeutics|January 6, 2021
A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement BiomarkerChristine Huynh, Andrea Henrich, Daniel S Strasser, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 5, 2012
Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humansMatthias Hoch, Justin L Hay, Petra Hoever, et al.
Clinical Pharmacology and Therapeutics|September 8, 2020
Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium DietPierre Gueneau de Mussy, Patricia N Sidharta, Gregoire Wuerzner, et al.
Clinical Pharmacology and Therapeutics|April 24, 2003
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertensionRobyn J Barst, Dunbar Ivy, Jasper Dingemanse, et al.
Clinical and Translational Science|July 9, 2024
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexantIngrid Koopmans, Daphne Geerse, Lara de Ridder, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|January 27, 2005
Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertensionShigetake Sasayama, Takeyoshi Kunieda, Hitonobu Tomoike, et al.
Molecular Genetics and Metabolism|May 19, 2009
Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosisGustavo H B Maegawa, Paul L M van Giersbergen, Sandra Yang, et al.
Pageof 24

Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
Journal of Clinical Pharmacology|September 17, 2009
Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 studyEkkehard Gruenig, Evangelos Michelakis, Jean-Luc Vachiéry, et al.
Clinical Drug Investigation|May 31, 2007
Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorderLuís Ferreira, Maria-Luísa Figueira, Alberto Bessa-Peixoto, et al.
The European Respiratory Journal|June 2, 2012
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertensionLaurent Savale, Romain Magnier, Jérôme Le Pavec, et al.
Clinical Pharmacology and Therapeutics|January 6, 2021
A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement BiomarkerChristine Huynh, Andrea Henrich, Daniel S Strasser, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 5, 2012
Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humansMatthias Hoch, Justin L Hay, Petra Hoever, et al.
Clinical Pharmacology and Therapeutics|September 8, 2020
Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium DietPierre Gueneau de Mussy, Patricia N Sidharta, Gregoire Wuerzner, et al.
Clinical Pharmacology and Therapeutics|April 24, 2003
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertensionRobyn J Barst, Dunbar Ivy, Jasper Dingemanse, et al.
Clinical and Translational Science|July 9, 2024
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexantIngrid Koopmans, Daphne Geerse, Lara de Ridder, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|January 27, 2005
Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertensionShigetake Sasayama, Takeyoshi Kunieda, Hitonobu Tomoike, et al.
Molecular Genetics and Metabolism|May 19, 2009
Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosisGustavo H B Maegawa, Paul L M van Giersbergen, Sandra Yang, et al.
Pageof 24